Remifentanil in Extracorporeal Shock Wave Lithotripsy

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the analgesic efficacy and side effects induced by administration of two different infusion rates of remifentanil, 0,05 mcg/ Kg/ min versus 0,1mcg/ Kg/ min, in order to determine which one is the most appropriate analgesic treatment to face extracorporeal shock wave lithotripsy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Roma La Sapienza
• Treatments: Remifentanil

Criteria

Inclusion Criteria:

• ASA (American Society of anaesthesiology) physical status between the I and class II

• Body mass index (BMI) between 18 and 30.

Exclusion Criteria:

• Patients who were unable to give informed consent or with diagnosis of depression

• Concurrent treatment with antidepressant

• Anxiolytic or with opioids or with history of abuse and dependence from these substances

• Allergy or intolerance to drugs administered in this study

• Severe cognitive deficits or psychiatric disorders

• Liver or renal impairment (aspartate aminotransferase > 40 UI/L alanine aminotransferase > 40 UI/L, creatinine > 2mg/dL)

• Abnormal values of coagulation (International normalized ratio > 1,2), platelet(< 100.000/µL), arrhythmias and / or defect of atrioventricular conduction.